Ubs Oconnor LLC Alnylam Pharmaceuticals, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 10,000 shares of ALNY stock, worth $2.69 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$2.69 Million% of portfolio
0.14%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
671Shares Held
109MCall Options Held
1.23MPut Options Held
1.18M-
Capital World Investors Los Angeles, CA16.5MShares$4.44 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.43 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.57 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.41 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.33 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...